LONDON (Reuters) - Health authorities in England have rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing its use in children and young people.
The National Institute for Health and Care Excellence (NICE) said Kymriah was not cost-effective for adult lymphoma. That contrasts with a green light for youngsters with aggressive leukemia when other drugs have failed.
NICE said the Swiss drugmaker had offered a confidential discount on the list price of 282,000 pounds ($372,000) per patient, but this was still above the level considered to be an acceptable use of resources.
Despite the preliminary rebuttal, NICE said it welcomed “further discussions” around the cost-effectiveness of Kymriah. NICE is the body that decides if new treatments are worth using on the state health service in England and Wales.
The decision on Kymriah in adults is in line with the rejection of a rival CAR-T treatment for adult lymphoma from Gilead Sciences.
Still, Novartis said it was surprised and disappointed, adding it would work with NICE to find a way to make Kymriah available to adults.
“This relates to individuals who have already failed two previous therapies, and for the vast majority of this population, life expectancy can be counted in months rather than years,” the company said.
Kymriah and Gilead’s Yescarta are chimeric antigen receptor T-cell therapies, or CAR-Ts, which reprogram the body’s own immune cells to attack malignant cells.
The treatments represents a new approach to fighting cancer, since the therapy involves extraction of infection-fighting cells from a patient. These cells are then genetically engineered to recognize cancer cells and infused back.
The process is complex and expensive but it offers hope for people with certain kinds of blood cancer who have exhausted all other treatment options.
Reporting by Ben Hirschler; editing by Jason Neely
Our Standards: The Thomson Reuters Trust Principles.